Complement Profile Panel (13-Plex)
Indications: Use this test to assess complement activation, deficiency, or dysregulation.
ANALYTES / BIOMARKERS
Adipsin (Factor D), C1q, C2, C3, C3b/iC3b, C4, C4b, C5, C5a, Factor B, Factor H, Factor I, Mannose-Binding Lectin (MBL)
TURNAROUND-TIME (TAT)
1-5 days
SAMPLE STABILITY
In vitro complement activation is likely to occur if samples are not stored and transported appropriately - separate plasma and freeze as soon as possible.
PROCEDURE / TECHNIQUE
Luminex® 100/200 (Addressable LASER Bead Immunoassay)
REFERENCE RANGE
Available for plasma-EDTA only. See example reports.
CLINICAL ASSOCIATIONS
Use this test to identify relevant therapy targets, determine disease mechanisms, and diagnose or monitor the following conditions associated with complement system activation, regulation, and dysfunction:
- Autoimmune Diseases: Assess autoimmune conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, where abnormal levels of complement components like C1q, C3, C4, and Mannose-Binding Lectin (MBL) can indicate complement activation and immune complex formation.
- Infectious Diseases: Evaluate the immune response in bacterial, viral, and fungal infections. Elevated levels of complement activation products like C3a, C5a, and Factor B can indicate an active immune response to infection.
- Complement Deficiencies: Support assessments of congenital deficiencies in complement components such as C2, C3, C4, and Factor H, which can predispose individuals to recurrent infections and autoimmune diseases.
- Kidney Diseases: Monitor complement-mediated kidney diseases such as membranoproliferative glomerulonephritis (MPGN) and atypical hemolytic uremic syndrome (aHUS), where complement components like C3, C3b/iC3b, Factor H, and Factor I are involved in disease pathogenesis.
- Inflammatory Conditions: Assess chronic inflammatory conditions such as inflammatory bowel disease (IBD) and vasculitis, where elevated levels of complement activation products like C5a and Factor D can indicate ongoing inflammation and tissue damage.
- Sepsis and Critical Illness: Diagnose and monitor sepsis and systemic inflammatory response syndrome (SIRS), where increased levels of complement activation fragments such as C3a, C5a, and sC5b-9 are markers of systemic inflammation and immune activation.
The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Cytokine levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.
See example report below.